Cannasouth Ltd
NZX:CBD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.7), the stock would be worth NZ$0.1 (0% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | NZ$0.1 |
0%
|
| 3-Year Average | 0.7 | NZ$0.1 |
0%
|
| 5-Year Average | 1.4 | NZ$0.2 |
+104%
|
| Industry Average | 4 | NZ$0.58 |
+496%
|
| Country Average | 1.8 | NZ$0.26 |
+164%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| NZ |
|
Cannasouth Ltd
NZX:CBD
|
32.4m NZD | 0.7 | -3.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 30.9 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 6.7 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 5.8 | 27.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.9 | 19.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 5.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 1.8 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 6.3 | 16.5 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 1 |
| Median | 1.8 |
| 70th Percentile | 3.4 |
| Max | 11.6 |
Other Multiples
Cannasouth Ltd
Glance View
Cannasouth Ltd. is a biopharmaceutical, research and development company, which develops medicinal cannabis products. The firm focuses on the commercial development of the medically beneficial attributes of cannabinoid compounds such as Cannabidiol (CBD), Tetrahydrocannabinol (THC) and associated chemical structures that are produced by the cannabis plant.
